Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking in American Conference Institute’s (ACI) Inaugural Summit on GLP-1 Law & Policy on July 24. Serving as the conference co-chair, Faget will explore how stakeholders can navigate risk and understand new regulation in the weight loss drug market.
The weight loss drug market, now exceeding US$100 billion, is rapidly expanding. ACI’s conference will feature industry leaders for a discussion focused on the opportunities and challenges of this booming industry.
Key event topics include:
- Regulatory Compliance & Market Strategies
- Navigating U.S. Food & Drug Administration (FDA), Federal Trade Commission (FTC), and Centers for Medicare & Medicaid Services (CMS) oversight under a new administration.
- Intellectual Property & Exclusivity Risks
- Understanding how patent cliffs and biosimilar competition could reshape the market.
- Compounding & Telehealth Disruption
- Examining regulatory battles over compounded GLP-1 drugs and their impact on traditional pharma.
- Reimbursement & Payer Strategies
- Addressing insurer pushback, Medicare drug pricing negotiations, and pharmacy benefit manager strategies.
- Litigation & Liability Risks
- Preparing for mass tort risks, product liability concerns, and class action lawsuits.
- Investment & Strategic Deals.
- Exploring M&A trends, venture capital outlook, and the licensing models influencing the future of weight loss pharmaceuticals.